MiNK Therapeutics begins enrolling 4-8 patients per site monthly in a phase 2 ARDS study for its agenT-797 therapy.
MiNK Therapeutics initiated enrollment in a randomized phase 2 trial for agenT-797, targeting acute lung injury and acute respiratory distress syndrome (ARDS) in the U.S. The company expects 4-8 patients per site per month starting in September 2026.
The trial follows execution progress highlighted in the Q2 2026 earnings call, where CEO Jennifer Buell emphasized the therapy’s advancement into later-stage testing. No prior phase 2 data for ARDS was disclosed in the update.
The announcement reflects MiNK’s focus on expanding its clinical pipeline for critical care therapies, though no immediate market reaction was reported.